ABBVIE INC. (ABBV)
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
BRAEMAR HOTELS & RESORTS EXTENDS RITZ-CARLTON LAKE TAHOE MORTGAGE LOAN
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Norwegian Cruise Line Names Lee Applbaum as Chief Marketing Officer
Pathfinder Bancorp, Inc. Declares Dividend
Cogent Communications Announces Closing of Sale of 10 Data Center Facilities
Ventas Announces Second Quarter 2026 Earnings Release Date and Conference Call
Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
BNY Mellon Municipal Bond Closed-End Funds Declare Distributions